Connect Biopharma is trading 8.77% higher at $2.66 in pre-market, possibly reflecting continued interest ahead of September clinical readouts, though the catalyst remains unconfirmed.
- Shares rose 6.52% to $2.45 during the August 25, 2026 session.
- No new company-specific announcement or overnight earnings release was identified for August 26.
- The latest material update was August 12 financial results, including completed Phase 2 Seabreeze STAT enrollment and expected September topline data; that update does not clearly explain the move. Confidence is low.